Persistent URL of this record https://hdl.handle.net/1887/103657
In Collections
This item can be found in the following collections:
Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial
- All authors
- McInnes, I.B.; Sieper, J.; Braun, J.; Emery, P.; Heijde, D. van der; Isaacs, J.D.; Dahmen, G.; Wollenhaupt, J.; Schulze-Koops, H.; Kogan, J.; Ma, S.L.; Schumacher, M.M.; Bertolino, A.P.; Hueber, W.; Tak, P.P.
- Date
- 2014-02-28
- Journal
- Annals of the Rheumatic Diseases
- Volume
- 73
- Issue
- 2
- Pages
- 349 - 356